In fact, given that guidelines, recommendations, and the SmPC all imply that certolizumab may be better than other anti-TNF drugs, due to its structural differences and the lack of a fragment of crystallizable (Fc) portion, therefore, we would actually expect to see a higher use of this medication among pregnant psoriasis patients [13,14]. Here, TNF is linked to psoriasis.